Pharvaris NV has been added to the Nasdaq Biotechnology Index (NBI) as of December 2025. Inclusion in the NBI requires companies to meet eligibility criteria such as minimum market capitalization, average daily trading volume, and sufficient time as a public company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623703-en) on January 12, 2026, and is solely responsible for the information contained therein.